Cellectis (CLLS) Retained Earnings (2014 - 2026)
Cellectis (CLLS) recorded quarterly Retained Earnings of -$334.2 million in Q1 2026, down 25.38% quarter-over-quarter from -$266.5 million in Q4 2025, and down 1.4% on a YoY basis from -$338.9 million in Q1 2025.
Cellectis (CLLS) Retained Earnings (2014 - 2026) Analysis & Trends
Cellectis' Retained Earnings history runs 13 years deep, the most recent figure standing at -$334.2 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 1.4% year-over-year to -$334.2 million; the TTM figure through Mar 2026 stood at -$334.2 million (down 1.4% YoY), while the FY2025 annual figure was -$266.5 million, up 8.98% from the prior year.
- Retained Earnings was -$334.2 million for Q1 2026 at Cellectis, down from -$266.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$101.1 million in Q4 2023 to a low of -$696.1 million in Q1 2022.
- Historically, Retained Earnings has averaged -$328.1 million across 5 years, with a median of -$320.8 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 45.28% in 2022, then plunged 189.78% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$106.1 million in 2022, then rose by 4.79% to -$101.1 million in 2023, then slumped by 189.78% to -$292.8 million in 2024, then increased by 8.98% to -$266.5 million in 2025, then fell by 25.38% to -$334.2 million in 2026.
- The last three Retained Earnings figures came in at -$334.2 million (Q1 2026), -$266.5 million (Q4 2025), and -$266.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -334.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -334.17 Mn |
| Dec 31, 2025 | -266.54 Mn |
| Sep 30, 2025 | -266.59 Mn |
| Jun 30, 2025 | -266.59 Mn |
| Mar 31, 2025 | -329.56 Mn |
| Dec 31, 2024 | -292.85 Mn |
| Sep 30, 2024 | -405.80 Mn |
| Jun 30, 2024 | -405.73 Mn |
| Mar 31, 2024 | -405.81 Mn |
| Dec 31, 2023 | -101.06 Mn |
| Sep 30, 2023 | -304.99 Mn |
| Jun 30, 2023 | -305.39 Mn |
| Mar 31, 2023 | -439.22 Mn |
| Dec 31, 2022 | -106.14 Mn |
| Sep 30, 2022 | -330.60 Mn |
| Jun 30, 2022 | -320.81 Mn |
| Mar 31, 2022 | -696.06 Mn |
| Dec 31, 2021 | -114.20 Mn |
| Sep 30, 2021 | -586.72 Mn |
| Jun 30, 2021 | -586.28 Mn |